Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesse T Jacob

Showing results (131-140 of 144) with videos related to

Pageof 15
Sort By:
Mbio|January 27, 2021
Colistin Heteroresistance Is Largely Undetected among Carbapenem-Resistant <i>Enterobacterales</i> in the United StatesVictor I Band, Sarah W Satola, Richard D Smith, et al.
Ocular Immunology and Inflammation|August 31, 2021
Retinopathy and Systemic Disease Morbidity in Severe COVID-19Jessica G Shantha, Sara C Auld, Casey Anthony, et al.
Infection Control and Hospital Epidemiology|December 4, 2024
Respiratory equality: let's stop playing favorites with COVID-19 in the healthcare settingCatherine L Passaretti, Werner Bischoff, Justin Chan, et al.
JAMA|October 6, 2015
Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013Alice Y Guh, Sandra N Bulens, Yi Mu, et al.
Open Forum Infectious Diseases|January 17, 2025
An Observational Study to Determine the Prevalence of COVID-19 Among Hospitalized Patients With Multidrug-Resistant Enterobacterales Infections and Clinical Outcomes, 10 US Sites, 2020--2022Julian E Grass, Sandra N Bulens, Uzma A Ansari, et al.
Antimicrobial Agents and Chemotherapy|September 6, 2022
Whole-Genome Sequencing Reveals Diversity of Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Collected through CDC's Emerging Infections Program, United States, 2016-2018Richard A Stanton, Davina Campbell, Gillian A McAllister, et al.
Open Forum Infectious Diseases|November 16, 2022
Clinical Impact of Ceftriaxone Resistance in <i>Escherichia coli</i> Bloodstream Infections: A Multicenter Prospective Cohort StudyPranita D Tamma, Lauren Komarow, Lizhao Ge, et al.
Infection Control and Hospital Epidemiology|February 14, 2022
Epidemiology of extended-spectrum β-lactamase-producing Enterobacterales in five US sites participating in the Emerging Infections Program, 2017Nadezhda Duffy, Maria Karlsson, Hannah E Reses, et al.
BMJ Quality & Safety|May 23, 2024
Evaluation of hospital-onset bacteraemia and fungaemia in the USA as a potential healthcare quality measure: a cross-sectional studySurbhi Leekha, Gwen L Robinson, Jesse T Jacob, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 8, 2026
Escherichia coli ST131 Drives Carbapenem Use for E. Coli Bloodstream InfectionsNatalie A Mackow, Wanying Shao, Lizhao Ge, et al.
Pageof 15

Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Mbio|January 27, 2021
Colistin Heteroresistance Is Largely Undetected among Carbapenem-Resistant <i>Enterobacterales</i> in the United StatesVictor I Band, Sarah W Satola, Richard D Smith, et al.
Ocular Immunology and Inflammation|August 31, 2021
Retinopathy and Systemic Disease Morbidity in Severe COVID-19Jessica G Shantha, Sara C Auld, Casey Anthony, et al.
Infection Control and Hospital Epidemiology|December 4, 2024
Respiratory equality: let's stop playing favorites with COVID-19 in the healthcare settingCatherine L Passaretti, Werner Bischoff, Justin Chan, et al.
JAMA|October 6, 2015
Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013Alice Y Guh, Sandra N Bulens, Yi Mu, et al.
Open Forum Infectious Diseases|January 17, 2025
An Observational Study to Determine the Prevalence of COVID-19 Among Hospitalized Patients With Multidrug-Resistant Enterobacterales Infections and Clinical Outcomes, 10 US Sites, 2020--2022Julian E Grass, Sandra N Bulens, Uzma A Ansari, et al.
Antimicrobial Agents and Chemotherapy|September 6, 2022
Whole-Genome Sequencing Reveals Diversity of Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Collected through CDC's Emerging Infections Program, United States, 2016-2018Richard A Stanton, Davina Campbell, Gillian A McAllister, et al.
Open Forum Infectious Diseases|November 16, 2022
Clinical Impact of Ceftriaxone Resistance in <i>Escherichia coli</i> Bloodstream Infections: A Multicenter Prospective Cohort StudyPranita D Tamma, Lauren Komarow, Lizhao Ge, et al.
Infection Control and Hospital Epidemiology|February 14, 2022
Epidemiology of extended-spectrum β-lactamase-producing Enterobacterales in five US sites participating in the Emerging Infections Program, 2017Nadezhda Duffy, Maria Karlsson, Hannah E Reses, et al.
BMJ Quality & Safety|May 23, 2024
Evaluation of hospital-onset bacteraemia and fungaemia in the USA as a potential healthcare quality measure: a cross-sectional studySurbhi Leekha, Gwen L Robinson, Jesse T Jacob, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 8, 2026
Escherichia coli ST131 Drives Carbapenem Use for E. Coli Bloodstream InfectionsNatalie A Mackow, Wanying Shao, Lizhao Ge, et al.
Pageof 15